Lupin Limited (NSE:LUPIN)
1,949.60
-78.35 (-3.86%)
Apr 1, 2025, 1:30 PM IST
Lupin Revenue
Lupin had revenue of 57.68B INR in the quarter ending December 31, 2024, with 10.97% growth. This brings the company's revenue in the last twelve months to 220.02B, up 12.94% year-over-year. In the fiscal year ending March 31, 2024, Lupin had annual revenue of 200.11B with 20.25% growth.
Revenue (ttm)
220.02B
Revenue Growth
+12.94%
P/S Ratio
n/a
Revenue / Employee
11.45M
Employees
19,210
Market Cap
925.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
Mar 31, 2020 | 153.75B | 7.10B | 4.84% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Lupin News
- 9 days ago - Lupin Digital Health launches post-procedure home care guide in collaboration with American College of Cardiology - Business Upturn
- 15 days ago - Lupin receives U.S. FDA approval for 10 mg Amifampridine Tablets - Business Upturn
- 22 days ago - Lupin share price surges over 1.50% after US launch of Rivaroxaban, brokerages bullish - Business Upturn
- 24 days ago - Lupin launches FDA-approved Rivaroxaban Tablets USP, 2.5 mg in the US - Business Upturn
- 5 weeks ago - Lupin shares surge 2.35% as US FDA issues Establishment Inspection Report (EIR) for Somerset facility - Business Upturn
- 5 weeks ago - Lupin’s Somerset plant gets FDA approval following successful inspection - Business Upturn
- 7 weeks ago - Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% - Business Upturn
- 7 weeks ago - Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets - Business Upturn